FTSE 100 Live: FTSE 100 extends losses as oil tops $100 and inflation fears mount

FTSE 100 fell 1.12% to 10,691. Broker moves: HSBC downgraded Burberry to 'hold' with 1,200p target; RBC initiated AstraZeneca at 'outperform' with 14,500p target. Oil prices topped $100, raising inflation concerns. Brent crude rose 2.93% to $100.85. FTSE 250 also saw mixed broker activity.

Original reporting
Published Sep 9, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 1:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMacro economy
Primary signal
$AZN
Bullish
medium confidence
Mentioned
$AZN · $CCC
Relevance
4/10
AlphAI data visualization · based on proactiveinvestors.co.uk
Decision brief

The 30-second read

$AZNBullishLow
01

Why it matters

The tradable signal is mostly macro and positioning. Single-name items include Burberry’s downgrade, AstraZeneca’s RBC initiation, and Aberdeen’s chair-designate appointment, but the broader index move is attributed to oil and inflation dynamics.

02

Market read

Traders should treat this primarily as a macro-driven risk-off tape, with selective single-name catalysts from broker actions and governance news.

03

What to watch

The piece notes investors await a US Treasury bond buyback announcement, which could quickly change rate expectations and reverse parts of the equity move.

Relevance 4/10Novelty 3/10Timing: intraday, during the FTSE 100 session as oil tops $100 and broker notes hit

Background

This is a London market wrap describing FTSE 100 weakness, broker rating changes in select FTSE names, and macro drivers including Brent crude above $100 and inflation fears.

Company-level read

Ticker impact

$AZNBullishMedium confidence
Context

RBC began coverage of AstraZeneca at 'outperform' with a 14,500p target, introducing a fresh analyst stance for AZN.

Expected impact

May provide relative support versus other FTSE names, but likely muted by broad index risk from oil and inflation.

Evidence & confidence

The catalyst is a new coverage initiation with a stated target, yet the article frames the broader move as macro-driven.

$CCCNeutralLow confidence
Context

Computacenter (FTSE 250) saw opposing broker calls, signaling mixed sentiment for CCC during the session.

Expected impact

Near-term volatility likely higher, with direction uncertain given 'opposing calls' framing.

Evidence & confidence

The article does not specify the direction or magnitude of each call, only that they were mixed.

Market effects

Oil above $100 is framed as the main driver, feeding inflation and rate-elevated-for-longer concerns that pressure retailers and energy-intensive businesses.

UK equities are trading near session lows with US futures subdued, suggesting cross-Atlantic risk sentiment remains cautious.

Middle East supply disruption risk and inflation expectations are the transmission channels to global equities and rates.

Counterpoint

The article’s oil-inflation narrative may be overextended intraday; commodity strength could keep some energy-linked names supported even if the index drifts lower.

Key entities

  • FTSE 100

    UK blue-chip benchmark described as down 1.12% near the session low, driven by oil and inflation fears.

  • Brent crude

    Brent is reported above $100, with Middle East tensions cited as the supply-risk driver.

  • Burberry Group

    Broker cut to 'hold' with a 1,200p target.

  • AstraZeneca

    RBC initiated coverage at 'outperform' with a 14,500p target.

  • Aberdeen Group

    Appointed Torbjörn Magnusson as chair-designate, pending regulatory approval.

Related articles

$AZNMed

AstraZeneca To Present Overall Survival Data From Four Pivotal Phase III Trials Featuring Sone-Ve, IMFINZI, TAGRISSO And Savolitinib

AstraZeneca will present data from four Phase III trials at the ESMO Congress, including results for Sone-Ve, IMFINZI, TAGRISSO, and Savolitinib. The trials focus on treatments for gastric, lung, and bladder cancers, with some showing statistically significant overall survival benefits. The data will be presented October 23-27, 2026.

$AZNMed

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

AstraZeneca will present data from four Phase III trials at ESMO 2026, featuring Sone-Ve, IMFINZI, TAGRISSO, and savolitinib. Key trials include CLARITY-Gastric01 for Sone-Ve in gastric cancer, SAFFRON for TAGRISSO plus savolitinib in lung cancer, and VOLGA and DeLLphi-305 for IMFINZI combinations in bladder and lung cancers. The company aims to showcase the potential of these treatments to set new standards of care.

$LLYMed

Your Questions Answered: Foundayo’s EU Panel Backing, Enspryng for TED, Gilead’s Masked TCE Bet, FDA’s Rare Disease Overhaul, and More

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

$AZNMed

AstraZeneca: to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, Imfinzi, Tagrisso and Orpathys

AstraZeneca will present overall survival data from four pivotal Phase III trials at ESMO 2026, featuring Sone-Ve, Imfinzi, Tagrisso, and Orpathys. The trials focus on bladder, lung, and gastric cancers, showcasing innovative combinations and precision medicine. Key data includes CLARITY-Gastric01 for Sone-Ve, SAFFRON for Tagrisso plus Orpathys, and VOLGA and DeLLphi-305 for Imfinzi combinations. AstraZeneca aims to redefine cancer treatment standards with these findings.